Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
addClaim

The SIK Axis and Cardiovascular Disease: Selenium-Dependent Selenoproteins, CoQ10-FSP1 Anti-Ferroptotic Defense, and T3-Mediated Coronary Vasodilation as Three Convergent Determinants of Cardiac Mitochondrial Protection

Authors: Ann, Grace;

The SIK Axis and Cardiovascular Disease: Selenium-Dependent Selenoproteins, CoQ10-FSP1 Anti-Ferroptotic Defense, and T3-Mediated Coronary Vasodilation as Three Convergent Determinants of Cardiac Mitochondrial Protection

Abstract

[SUPERSEDED — This is a duplicate upload. The canonical version of this paper is available at https://doi.org/10.5281/zenodo.20563299] This paper proposes that cardiac mitochondria are governed by the Selenoprotein Axis framework through three specific selenoprotein-dependent mechanisms: (1) TrxR2, the mitochondria-specific thioredoxin reductase selenoenzyme, provides primary redox defense in the cardiac inner mitochondrial membrane; (2) GPx4 suppresses ferroptosis in cardiomyocytes, documented in ischemia-reperfusion injury, doxorubicin cardiotoxicity, and heart failure; (3) T3-mediated coronary artery vasodilation maintains perfusion pressure through selenium-dependent deiodinase T4-to-T3 conversion. The KiSel-10 randomized controlled trial demonstrated 40% reduction in cardiovascular mortality over 12 years from selenium yeast 200mcg plus CoQ10 200mg daily in selenium-insufficient elderly populations. Keshan disease provides historical proof of concept. All claims are hypothesis-level requiring prospective clinical confirmation.

Powered by OpenAIRE graph
Found an issue? Give us feedback